Risk of Postconcussive Symptoms Down With Early Exercise

Share this content:
Risk of Postconcussive Symptoms Down With Early Exercise
Risk of Postconcussive Symptoms Down With Early Exercise

TUESDAY, Dec. 20, 2016 (HealthDay News) -- Participation in physical activity within seven days after injury is associated with reduced rates of persistent postconcussive symptoms (PPCS), according to a study published in the Dec. 20 issue of the Journal of the American Medical Association.

Anne M. Grool, M.D., Ph.D., from the Children's Hospital of Eastern Ontario Research Institute in Ottawa, Canada, and colleagues examined the correlation between participation in physical activity within seven days after injury and the incidence of PPCS in a prospective multicenter cohort study. A total of 3,063 children and adolescents with acute concussion from nine emergency departments were included.

The researchers found that PPCS at 28 days occurred in 30.4 percent of the 2,413 participants who completed the primary outcome assessment and had data available on participation in physical activity at day seven; 69.5 percent had participated in early physical activity, while 30.5 percent had no physical activity. Early physical activity participants had lower risk of PPCS than those with no physical activity in unadjusted analysis (24.6 versus 43.5 percent). On propensity-score matching and on inverse probability of treatment weighting analyses, early physical activity correlated with lower PPCS risk. PPCS rates were lower for participants of light aerobic activity, moderate activity, and full-contact activity compared with no physical activity among those who were symptomatic at day seven.

"A well-designed randomized clinical trial is needed to determine the benefits of early physical activity following concussion," the authors write.

Several authors disclosed financial ties to the publishing industry.

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths